Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease

Author(s): Highland KB, Strange C, Heffner JE

Abstract

Background: There is no consensus on the effectiveness of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD).

Purpose: To evaluate the long-term effects of inhaled corticosteroids on the rate of FEV1 decline in patients with COPD.

Data sources: MEDLINE, EMBASE, CISCOM, and AMED databases and the Cochrane Library (1966 to December 2002), reference lists from identified articles, and consultation with experts. Searches were not limited to the English language.

Study selection: Randomized, placebo-controlled trials that examined the rate of FEV1 decline as a primary outcome in patients with COPD.

Data extraction: Two reviewers independently extracted the data by using predetermined criteria.

Data synthesis: For the six studies that met the inclusion criteria, the summary estimate for the difference in FEV1 decline between the placebo and treatment groups was -5.0 +/- 3.2 mL/y (95% CI, -11.2 to 1.2 mL/y; P = 0.11).

Conclusions: The use of inhaled corticosteroids was not associated with the rate of FEV1 decline in 3571 patients followed for 24 to 54 months.

Similar Articles

Chronic obstructive pulmonary disease surveillance - United States, 1971-2000

Author(s): Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC

Bronchodilators in chronic air-flow limitation

Author(s): Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, et al.

Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD

Author(s): Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, et al.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Author(s): Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al.

Contemporary management of chronic obstructive pulmonary disease: scientific review

Author(s): Sin DD, McAlister FA, Man SF, Anthonisen NR

Oral theophylline for chronic obstructive pulmonary disease

Author(s): Ram FS, Jones PW, Castro AA, DeBerito JA, Atallah AN, et al.

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

Author(s): Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al.

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

Author(s): Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, et al.

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study

Author(s): Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, et al.

Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial

Author(s): Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, et al.

Corticosteroids contribute to muscle weakness in chronic airflow obstruction

Author(s): Decramer M, Lacquet LM, Fagard R, Rogiers P

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

Author(s): Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, et al.

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

Author(s): Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, et al.

Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients

Author(s): Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

Author(s): Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, et al.

Marked sympathetic activation in patients with chronic respiratory failure

Author(s): Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S

Appropriateness of domiciliary oxygen delivery

Author(s): Guyatt GH, McKim DA, Austin P, Bryan R, Norgren J, et al.

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial

Author(s): Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, et al.

Controlled trial of oral prednisone in outpatients with acute COPD exacerbation

Author(s): Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease

Author(s): Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, et al.

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

Author(s): Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, et al.

Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis

Author(s): Jorgensen AF, Coolidge J, Pedersen PA, Peterson KP, Waldorff S, et al.